Evidence map›Paper›PMID 22998582›Full record

ArticleJournal of proteome research2012

Improving international research with clinical specimens: 5 achievable objectives.

Joshua LaBaer

Abstract read
In one paragraph

Article in Journal of proteome research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Joshua LaBaerVirginia G. Piper Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, 1001 South McAllister Avenue, Tempe, Arizona 85287-5001, USA. jlabaer@asu.edu

Funding

Contiunation and Enhancement of the PSI: Biology-Materials RepositoryU01GM098912 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI LABAER, JOSHUA · 2011 to 2015
$6.9M
Biomarker Detection Using NAPPA Tumor Antigen ArraysU01CA117374 · NCI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ANDERSON, KAREN SUE, LABAER, JOSHUA · 2005 to 2015
$6.2M
NCI NIH HHS 5U01CA117374NCI NIH HHS U01 CA117374NIGMS NIH HHS U01 GM098912NIGMS NIH HHS U01GM098912PHS HHS H47328
6 · The paper itself

Abstract

Our increased interest in translational research has created a large demand for blood, tissue, and other clinical samples, which find use in a broad variety of research including genomics, proteomics, and metabolomics. Hundreds of millions of dollars have been invested internationally on the collection, storage, and distribution of samples. Nevertheless, many researchers complain in frustration about their inability to obtain relevant and/or useful samples for their research. Lack of access to samples, poor condition of samples, and unavailability of appropriate control samples have slowed our progress in the study of diseases and biomarkers. In this perspective, I focus on five major challenges that thwart clinical sample use for translational research and propose near term objectives to address them. They include: (1) defining our biobanking needs; (2) increasing the use of and access to standard operating procedures; (3) mapping interobserver differences for use in normalizing diagnoses; (4) identifying natural internal protein controls; and (5) redefining the clinical sample paradigm by building partnerships with the public. In each case, I believe that we have the tools at hand required to achieve the objective within 5 years. Potential paths to achieve these objectives are explored. However we solve these problems, the future of proteomics depends on access to high quality clinical samples, collected under standardized conditions, accurately annotated and shared under conditions that promote the research we need to do.

Indexed as

International CooperationSoftwareBiological Specimen BanksBiomarkersCalibrationCommunity ParticipationDatabases, FactualHumansObserver VariationPathology, ClinicalProteomicsReference StandardsTranslational Research, BiomedicalBiomarkers

Identifiers

PMID22998582
PMCPMC3640360

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.